ABSTRACT
ObjectiveTo explore the efficacy of 131 Ⅰ treatment in Graves' disease,and to analyze the related factors.MethodIn 87 patients with Graves' disease,thyroid uptake ratio( TUR ) and its effective half-life(EHL) were compared before and after 131 Ⅰ treatment.The weight of thyroid gland was evaluated with radio-imaging and type B ultrasonography.ResultThe dose of 131 Ⅰ was ( 185.2 ± 148.0 ) MBq.The TUR of tracer dose and therapeutic 131 Ⅰ dose were 76.5 ％ ±8.2％ and 73.3 ％ ±9.0％ ( t =2.451,P =0.008 ).The EHL were ( 5.2±0.7 ) and ( 5.0 ±0.8 )days,respectively ( t =1.998,P =0.023 ).After followe-up of ( 57.0 ±26.3 ) months,49 patients ( 56.3 ％ ) became euthyroid,14 ( 16.1％ )manifested delayed hypothyroidism,and 24 (27.6％)remained in hyperthyroidism.Thyroid autoantibodies were found in 34.5％ patients,of whom,the incidence of hypothyroidism was higher in patients with positive autoantibodies than those with negative ones (30.0％ vs 8.8％,x2 =6.560,P =0.009 ).ConclusionBoth TUR and EHL of therapeutic doses of 131 Ⅰ are lower than the tracer doses.Positive thyroid autoantibodies may affect the outcome of the 131 Ⅰ treatment.
ABSTRACT
Objective To observe changes of thyroid weight and function after 131 I therapy in Graves′ diseaseandtooptimiseradiationdose for treatment of Graves′ disease. Methods From 1995 to 1998, 103 patients with Graves′ disease were selected (nodule was not found by palpation and nuclear scintigraphy). The mean age was 43 (range 27～64) years. Thyroid weight was estimated by nuclear scintigraph (SC) and ultrasound (US). Thyroid function was determined by serum TT 3, TT 4, FT 3, FT 4 and TSH levels. Results The oral dose of 131 I was (188.7?144.3)MBq. If the dose was larger than 555.0 MBq, it was divided into two doses orally. The thyroid weight of the patients before 131 I therapy was (54.8?32.3)g (SC) and (49.3?27.7)g (US), there was no significant difference between SC and US. The thyroid weight in 90 patients was significantly decreased from (51.5?23.4)g to (27.0?13.9)g by SC, and from (47.2?23.7)g to (20.6?8.4)g by US 6～7 months after 131 I treatment. Reduction of thyroid weight was correlated with that before therapy (determined by US) (r=0.49, P